Targeted Genomics on Wednesday announced a commercial collaboration with OraSure Technologies for direct-to-consumer celiac disease testing using the OraCollect-Dx saliva collection device and GlutenID test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.

nSAGE, Caszyme, and Vilnius University have joined forces to form a consortium which will develop a new, advanced diagnostics solution. The UNCOVER project will develop a universal, CRISPR-based diagnostics platform for accurate and rapid detection of infectious diseases. This platform will be versatile, user-friendly, applicable to both human and animal health, and will be easily programable to address a wide range of pathogens and disease biomarkers.

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.

Oxford Nanopore Technologies, the company behind a new generation of sequencing-based molecular analysis technologies, and Cepheid, a leading molecular diagnostics company, today announced a strategic collaboration to develop and commercialize a seamless end-to-end workflow that combines Cepheid's GeneXpert system for pre-sequencing sample and library preparation with Oxford Nanopore's rapid, information-rich molecular analysis platform.

Boditech Med, a global leader in point-of-care diagnostics, announced on the 7th that it held a successful completion ceremony for its new manufacturing facility located in Jhajjar, India. The new plant is a key part of the company’s strategy to strengthen its presence in the Indian, South Asian, and Middle Eastern markets through local production and enhanced cost competitiveness.

Manufacturing investments have taken center stage in recent years — from some pharma giants ramping up GLP-1 manufacturing capacity to meet soaring demand to other companies focusing on advanced capabilities that could ensure an adequate supply of vaccines.

Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced a collaboration with Sumitomo Pharma America, Inc. (SMPA) to develop the FoundationOne®Heme platform as a companion diagnostic to identify patients with acute leukemia with a KMT2A rearrangement, also known as mixed lineage leukemia (MLL) rearrangement, or NPM1 mutations for potential treatment with SMPA’s enzomenib (DSP-5336), an investigational menin inhibitor.